Abstract
There is a large body of evidence describing the utility of antidiabetes agents in people with chronic kidney disease (CKD). Clinical decisions should take into account the pharmacokinetic variability and potential adverse events seen when these agents are used in renally impaired patients. In this article, the authors review the literature and summarise which antidiabetes agents are safe, with dose reductions if necessary, in people with CKD.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 358-363 |
| Number of pages | 6 |
| Journal | Journal of Diabetes Nursing |
| Volume | 20 |
| Issue number | 10 |
| State | Published - 2016 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Endocrinology, Diabetes and Metabolism
- Advanced and Specialized Nursing
Cite this
Utility of antidiabetes medications in chronic kidney disease : A review. / Knezevich, Emily; Kueser, Annette.
In: Journal of Diabetes Nursing, Vol. 20, No. 10, 2016, p. 358-363.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Utility of antidiabetes medications in chronic kidney disease
T2 - A review
AU - Knezevich, Emily
AU - Kueser, Annette
PY - 2016
Y1 - 2016
N2 - There is a large body of evidence describing the utility of antidiabetes agents in people with chronic kidney disease (CKD). Clinical decisions should take into account the pharmacokinetic variability and potential adverse events seen when these agents are used in renally impaired patients. In this article, the authors review the literature and summarise which antidiabetes agents are safe, with dose reductions if necessary, in people with CKD.
AB - There is a large body of evidence describing the utility of antidiabetes agents in people with chronic kidney disease (CKD). Clinical decisions should take into account the pharmacokinetic variability and potential adverse events seen when these agents are used in renally impaired patients. In this article, the authors review the literature and summarise which antidiabetes agents are safe, with dose reductions if necessary, in people with CKD.
UR - http://www.scopus.com/inward/record.url?scp=85009247754&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85009247754&partnerID=8YFLogxK
M3 - Review article
VL - 20
SP - 358
EP - 363
JO - Journal of Diabetes Nursing
JF - Journal of Diabetes Nursing
SN - 1368-1109
IS - 10
ER -